Fibrocell Science

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

Exton, US
Size (employees)
52 (est)
Fibrocell Science is headquartered in Exton, US

Key People at Fibrocell Science

David Pernock

David Pernock

Chairman and Chief Executive Officer
Robert S. Langer

Robert S. Langer

John Maslowski

John Maslowski

Vice President, Scientific Affairs
Declan Daly

Declan Daly

Chief Operating Officer and Chief Financial Officer

Fibrocell Science Office Locations

Fibrocell Science has office in Exton
Exton, US

Fibrocell Science Metrics

Fibrocell Science Summary

Market capitalization

$31.4 m

Closing share price

Fibrocell Science's current market capitalization is $31.4 m.

Fibrocell Science Financials

Fibrocell Science's revenue is $200 k in FY, 2013 which is a 11.1% increase from the previous period.
FY, 2013FY, 2014FY, 2015Y, 2016


$200 k$180 k$492 k$355 k

Revenue growth, %


Net Income

($30.6 m)($25.7 m)($34.5 m)

Fibrocell Science Market Value History

Fibrocell Science Online Presence

Fibrocell Science Company Life

You may also be interested in